Patents Assigned to Merck
  • Combination of quinoline-4-carboxamides and benzonaphthyridine derivatives as antimalarial drug combination
    Publication number: 20210023087
    Abstract: A combination includes as a first active ingredient 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or pharmaceutically acceptable salt thereof and as a second active ingredient pyronaridine or a prodrug or pharmaceutically acceptable salt thereof. Also, a combination includes three antimalarial active ingredients, namely of 6-fluoro-2-(4-morpholin-4-ylmethyl-phenyl)-quinoline-4-carboxylic acid (2-pyrrolidin-1-yl-ethyl)-amide or a prodrug or salt thereof, pyronaridine or pharmaceutically acceptable salt thereof, and artemisinin or derivatives thereof. Further, pharmaceutical compositions include such combination. The combinations and pharmaceutical compositions are useful for the treatment and/or prevention of malaria.
    Type: Application
    Filed: April 9, 2019
    Publication date: January 28, 2021
    Applicant: Merck Patent GmbH
    Inventors: Thomas Spangenberg, Claude Oeuvray, Nada Abla
  • FILTRATION HEAD FOR A FILTER SYSTEM AND FUNNEL FOR USE IN CONJUNCTION WITH A FILTRATION HEAD
    Publication number: 20210023481
    Abstract: Filtration head (1) for a filter system, comprising base (2) including filter support (3) for removable filter element (4) and a fluid path from one side of filter element (4) on filter support (3), through filter element (4), and to drainage outlet (5) of base (2), and holder device (6) for removably attaching funnel (7) to base (2) to form a sample fluid reservoir on one side of filter element (4), wherein holder device (6) comprises ring-shaped element (8) configured to extend about bottom peripheral flange (7a) surrounding a lower end of funnel (7) and to selectively apply a biasing force on a radially outward protruding portion (7b) of bottom peripheral flange (7a) of funnel (7) to press funnel (7) against base (2). The filtration head allows the use of cardboard funnels without risk of liquid leakage between the funnel and the base.
    Type: Application
    Filed: April 3, 2019
    Publication date: January 28, 2021
    Applicant: MERCK PATENT GMBH
    Inventors: Didier METZ, Marisa HOHNADEL
  • Anti-LAG3 antibodies and antigen-binding fragments
    Patent number: 10898571
    Abstract: The present invention includes antibodies and antigen-binding fragments thereof that specifically bind to human or cynomolgous monkey LAG3 as well as immunoglobulin chains thereof and polynucleotides encoding the same along with injection devices comprising such antibodies or fragments. Vaccines including such antibodies and fragments as well as compositions comprising the antibodies and fragments (e.g., including anti-PD1 antibodies) are included in the invention. Methods for treating or preventing cancer or infection using such compositions are also provided. In addition, methods for recombinant expression of the antibodies and fragments are part of the present invention.
    Type: Grant
    Filed: December 4, 2018
    Date of Patent: January 26, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Linda Liang, Laurence Fayadat-Dilman, Rene De Waal Malefyt, Gopalan Raghunathan
  • Benzil monoketals and the use thereof
    Patent number: 10899852
    Abstract: The present invention relates to the use of hydrophilic compounds of the formula I as photopolymerisation initiators of polymerisable substance mixtures which comprise unsaturated compounds, or for the photochemical crosslinking of linear polymers, in which the parameters have the meaning indicated in Claim 1, to sealants for liquid-crystal displays which comprise the hydrophilic photoinitiators, to novel hydrophilic photoinitiators of the formula I, and to the liquid-crystal displays produced using these sealants.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 26, 2021
    Assignee: Merck Patent GmbH
    Inventors: Peer Kirsch, Qiong Tong, Alexander Hahn, Leo Weegels, Steffen Gnauck, Sven Schuepfer, Peter Leonhard, Claudia Enders
  • Combination of a PD-1 antagonist and a 4-1BB agonist for treating cancer
    Patent number: 10899840
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a selective 4-1 BB agonist, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.
    Type: Grant
    Filed: February 3, 2015
    Date of Patent: January 26, 2021
    Assignees: Pfizer Inc., Merck Sharp & Dohme Corp.
    Inventors: Craig Bennett Davis, Maria Theresa Koehler, Li Yan
  • Process for making beta 3 agonists and intermediates
    Patent number: 10899771
    Abstract: The present invention is directed to processes for preparing beta 3 agonists of Formula (I) and Formula (II) and their intermediates. The beta 3 agonists are useful in the treatment of certain disorders, including overactive bladder, urinary incontinence, and urinary urgency.
    Type: Grant
    Filed: October 1, 2019
    Date of Patent: January 26, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: John Y. L. Chung, Kevin Campos, Edward Cleator, Robert F. Dunn, Andrew Gibson, R. Scott Hoerrner, Stephen Keen, Dave Lieberman, Zhuqing Liu, Joseph Lynch, Kevin M. Maloney, Feng Xu, Nobuyoshi Yasuda, Naoki Yoshikawa, Yong-Li Zhong
  • Materials for electronic devices
    Patent number: 10903430
    Abstract: The present invention relates to compounds, compositions and formulations comprising same and to opto-electronic devices comprising the compounds and compositions according to the invention.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: January 26, 2021
    Assignee: Merck Patent GmbH
    Inventors: Anja Jatsch, Amir Hossain Parham, Thomas Eberle, Tobias Grossmann, Jonas Valentin Kroeber
  • Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases
    Patent number: 10899788
    Abstract: The present invention relates to Cyclic Phosphate Substituted Nucleoside Compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein in A, B, R1, R2, R3, Q and V are as defined herein. The present invention also relates to compositions comprising a Cyclic Phosphate Substituted Nucleoside Compound, and methods of using the Cyclic Phosphate Substituted Nucleoside Compounds for treating or preventing HCV infection in a patient.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: January 26, 2021
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Stephane Bogen, David Dukhan, Guillaume Brandt, Claire Pierra Rouviere, Cyril B. Dousson, Francois-Rene Alexandre
  • ANTI-TIGIT ANTIBODIES
    Publication number: 20210017276
    Abstract: The present invention relates to anti-TIGIT antibodies, as well as use of these antibodies in the treatment of diseases such as cancer and infectious disease.
    Type: Application
    Filed: July 27, 2020
    Publication date: January 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Sybil M.G. Williams, Wolfgang Seghezzi, Laurence Fayadat-Dilman, Linda Liang, Veronica Juan
  • PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE CELLULAR RETENTION OF COMPOUNDS
    Publication number: 20210015930
    Abstract: Phosphonate linkers and their use for delivering compounds with passive cell permeability into a cell wherein the phosphonate group facilitates cellular retention of the compound are described.
    Type: Application
    Filed: September 24, 2020
    Publication date: January 21, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Robert M. Garbaccio, Jeffrey C. Kern, James J. Mulhearn, Philip E. Brandish
  • Piperidine derivatives as liver X receptor beta agonists, compositions, and their use
    Patent number: 10894775
    Abstract: In its many embodiments, the present invention provides certain piperidine compounds of the Formula (I): and pharmaceutically acceptable salts thereof, wherein X, Y, R1, R2, R3, L, R4, L1, Q, and R5 are as defined herein. The novel compounds of the invention, and pharmaceutically acceptable compositions comprising a compound thereof, are useful as Liver X-? receptor (LXR?) agonists, and may be useful for treating or preventing pathologies related thereto. Such pathologies include, but are not limited to, inflammatory diseases and diseases characterized by defects in cholesterol and lipid metabolism, such as Alzheimer's disease.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: January 19, 2021
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael T. Rudd, Zhaoyang Meng, Jenny Wai, David Jonathan Bennett, Edward J. Brnardic, Nigel J. Liverton, Shawn J. Stachel, Yongxin Han, Paul Tempest, Jiuxiang Zhu, Xuewang Xu, Bin Zhu, Chuanman Huang
  • Powder formulation containing insect repellent
    Patent number: 10893675
    Abstract: The present invention relates to a powder formulation comprising at least one insect repellent and magnesium hydroxide carbonate, and to a process for the preparation of the formulation and to the use of the formulation for repelling insects.
    Type: Grant
    Filed: January 8, 2016
    Date of Patent: January 19, 2021
    Assignee: MERCK PATENT GMBH
    Inventors: Michael Termer, Frank Pfluecker, Lilia Heider, Alexandra Axt-Heidemann, Jutta Zur Lage
  • Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
    Patent number: 10894829
    Abstract: The invention provides methods for using and compositions of humanized antibodies that bind tau protein that is phosphorylated at the serine at position 413.
    Type: Grant
    Filed: January 17, 2020
    Date of Patent: January 19, 2021
    Assignees: TEIJIN PHARMA LIMITED, MERCK SHARP & DOHME CORP.
    Inventors: Hiroshi Eguchi, Takashi Murakami, Naoko Namiki, Akira Tanokura, Jeanne E. Baker, Sophie Parmentier Batteur, Angela Marie Jablonski, Daniel Stephen Malashock, Carl Mieczkowski, Gopalan (Raghu) Raghunathan
  • Liquid crystal medium containing polymerisable compounds
    Patent number: 10894918
    Abstract: The present invention relates to a liquid crystal (LC) medium comprising polymerisable compounds, to a process for its preparation, to its use for optical, electro-optical and electronic purposes, in particular in LC displays, and to LC displays comprising it.
    Type: Grant
    Filed: May 31, 2016
    Date of Patent: January 19, 2021
    Assignee: Merck Patent GmbH
    Inventors: Melanie Klasen-Memmer, Nils Greinert, Matthias Bremer, Konstantin Schneider, Christian Schoenefeld, Thomas Bauer
  • Liquid-Crystal Display Devices Containing Polymerisable Compounds
    Publication number: 20210009901
    Abstract: Liquid-crystal (LC) display devices comprising polymerisable compounds, processes and intermediates for the preparation of the devices and compounds, LC media comprising the compounds, and the use of the polymerisable compounds and LC media for optical, electro-optical and electronic purposes, in particular in LC displays, especially in LC displays of the polymer sustained alignment type.
    Type: Application
    Filed: July 21, 2020
    Publication date: January 14, 2021
    Applicant: Merck Patent GmbH
    Inventors: Dmitry USHAKOV, Kaja Christina DEING
  • TETRACYCLIC HETEROCYCLE COMPOUNDS USEFUL AS HIV INTEGRASE INHIBITORS
    Publication number: 20210009262
    Abstract: The present invention relates to Tetracyclic Heterocycle Compounds of Formula and pharmaceutically acceptable salts or prodrug thereof, wherein A, X, R1, R2, R3 and Ware as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Heterocycle Compound, and methods of using the Tetracyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.
    Type: Application
    Filed: September 18, 2020
    Publication date: January 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Thomas H. Graham, Tao Yu, Yonglian Zhang, John A. McCauley
  • POLYPEPTIDES BINDING ADAMTS5, MMP13 AND AGGRECAN
    Publication number: 20210008160
    Abstract: The present invention relates to polypeptides binding Aggrecan as well as ADAMTS5 and/or MMP13, more in particular to polypeptides that comprise or essentially consist of immunoglobulins binding Aggrecan as well as immunoglobulins binding ADAMTS5 and/or immunoglobulins binding MMP13 (also referred to herein as “polypeptides of the invention”, and “immunoglobulin(s) of the invention”, respectively).
    Type: Application
    Filed: June 4, 2018
    Publication date: January 14, 2021
    Applicants: Merck Patent GmbH, ABLYNX NV
    Inventors: Soren STEFFENSEN, Gerald BESTE, Hans GUEHRING, Lars TOLEIKIS, Christoph LADEL, Sven LINDEMANN, Roland KELLNER, Ralf GUENTHER
  • AZA-BENZOTHIOPHENE COMPOUNDS AS STING AGONISTS
    Publication number: 20210009608
    Abstract: Compounds of general formula (I), and their pharmaceutically acceptable salts, wherein R1, R2, R3, R5, R6, R8, R9, A, X1, X2, and X3 are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are compositions comprising such compounds, processes for the synthesis of such compounds, and to uses of such compounds, including administration of such compounds to induce immune response, to induce STING-dependent type I interferon production, and/or to treat a cell proliferation disorder, such as cancer.
    Type: Application
    Filed: March 28, 2019
    Publication date: January 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Brandon D. Cash, Jared N. Cumming, Duane E. DeMong, Andrew M. Haidle, James P. Jewell, Matthew A. Larsen, Min Lu, Ryan D. Otte, Brandon M. Taoka, Benjamin Wesley Trotter, Quang T. Truong
  • Process for making electronic device
    Patent number: 10892414
    Abstract: Described herein is a process for the preparation of an electronic device such as an organic electroluminescent device (OLED), wherein two adjacent functional layers having an interface are formed from solution in a kinetically controlled manner. The process is particularly suitable for fast and efficient production of electronic devices by printing or coating processes. The description further relates to an electronic device which is obtainable by said process.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: January 12, 2021
    Assignee: Merck Patent GmbH
    Inventors: Gaelle Béalle, Christoph Leonhard, Hsin-Rong Tseng, Manuel Hamburger, Beate Burkhart, Katja Maria Scheible, Anja Jatsch
  • TYROSINE-SPECIFIC FUNCTIONALIZED INSULIN AND INSULIN ANALOGS
    Publication number: 20210002345
    Abstract: The present invention relates to tyrosine-specific functionalized insulin analogs and processes of making such tyrosine-specific functionalized insulin analogs using R-3H-1,2,4-triazoline-3,5-(4H)diones (PTAD).
    Type: Application
    Filed: March 18, 2019
    Publication date: January 7, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Ahmet Kekec, Nancy Jo Kevin, Bing Li, Songnian Lin, Craig A. Parish, Weijuan Tang